RxDoctor Payments DataLook up a doctor →

Roger Diegel, MD

Rheumatology · Kalispell, MTNPI 1770660896

Payments from drug & device makers

$1,875,707in general payments, 2019–2025

Across 835 payments — averaging $2246.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$865K
  • Eli Lilly$489K
  • Sun Pharmaceutical Industries Inc.$216K
  • E.r. Squibb & Sons, L.L.C.$111K
  • Lilly USA, LLC$79K
  • Janssen Research & Development, LLC$56K
  • plus $60K from 13 others
$699in research payments, 2019–2025

Across 4 payments — averaging $174.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$699

What the payments were for

  • Consulting fees$1,8002%
  • Speaking & faculty fees$62,30076%
  • Travel & lodging$12,61615%
  • Food & beverage$5,0916%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few rheumatology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$69,260
Medicare patients
323
Services billed
1,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab51$378,272
EnbrelEtanercept28$325,464
Humira(Cf)Adalimumab34$303,313
RinvoqUpadacitinib36$283,557
Taltz SyringeIxekizumab18$233,364
XeljanzTofacitinib Citrate25$149,294
Enbrel SureclickEtanercept18$132,553
Xeljanz XrTofacitinib Citrate13$74,729
Orencia ClickjectAbatacept12$65,655
Hydroxychloroquine Sulfate636$25,066
MethotrexateMethotrexate Sodium494$13,129
Prednisone399$3,705
Mycophenolate Mofetil28$2,915
Leflunomide14$2,120
Celecoxib54$1,418

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq$865,451$586,87170 claims
AmgenEnbrel$20,473$325,46428 claims
PfizerXeljanz$38,027$149,29425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few rheumatology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other rheumatology in Kalispell

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →